The company first studied immunogenic and antibody responses to 23 peptide epitopes in preclinical trials before selecting multiple peptides for its vaccine candidate, DPX-COVID-19. The vaccine is intended to work through multiple mechanisms to prevent infection and inhibit the virus from entering cells.

Vaccine development remains on schedule, and IMV plans to conduct a phase I clinical study this summer. The company is also performing vaccination-challenge preclinical assays in animal models with the intent to publish results later this year.

Big data analysis of images may aid vaccine development
A new pipeline that combines high-dimensional microscopy with big data analysis to gain molecular insights in T-cell biology and vaccine development was...

AGC to manufacture Takara Bio's COVID-19 vaccine
In the fight against COVID-19, AGC Biologics, a contract development and manufacturing organization, is partnering with Takara Bio to manufacture plasmid...

Inovio vaccine proves potent against SARS-CoV-2 in preclinical trials
Inovio announced that preclinical data for its INO-4800 vaccine candidate were published in Nature Communications on May 20. The results suggesting...

Bharat, TJU partnering on COVID-19 vaccine
Bharat Biotech and Thomas Jefferson University (TJU) of Philadelphia have signed a deal to develop a new vaccine for COVID-19.

Moderna lays out plan for mRNA-1273 vaccine
Moderna released interim clinical data about mRNA-1273, its vaccine candidate against SARS-CoV-2, from the phase I study led by the U.S. National Institute...